New shot aims to tame rare liver virus
Disease control
Ongoing
This study tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of the drug daily for 48 weeks, or wait for treatment. The goal is to see if the drug can lower the virus level and…
Phase: PHASE2 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC